PMH4 2-YEAR OUTCOMES OF RISPERDAL® CONSTATM-THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

Article OPEN
Trakas, K; Talling, D; Balshaw, R; Love, L; Robinson, K;
(2003)
Share - Bookmark